MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MSA is a progressive ...

MELBOURNE, Australia and SAN FRANCISCO, March 02, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (TLSA) (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

A new study by the University of Turku and Turku University Hospital, Finland, found that a significant proportion of Parkinson's disease diagnoses are later corrected. Up to one in six diagnoses ...

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...